Quest Diagnostics Incorporated (DGX) Earnings Call Transcripts

Quest Diagnostics Incorporated's Latest Earnings Call - September 15, 2026

In the third quarter of fiscal year 2026, Quest Diagnostics reported revenue growth of approximately 8% and earnings growth of nearly 14%, signaling strong organic performance despite a shift in M&A strategy. The company guided for continued revenue growth in the range of 4% to 5% for the upcoming year, with management emphasizing the stability of their core business driven by chronic health conditions and an increasing focus on wellness testing. Notably, the company has shifted its growth strategy towards organic growth rather than relying heavily on acquisitions, with a significant portion of growth attributed to partnerships and new testing offerings.

Reported metrics

Guidance from management

Management maintained revenue growth guidance of 4% to 5% for fiscal year 2027, with earnings growth expected to remain strong, reflecting confidence in organic growth strategies.

What management said

I don't know if Sam gave some update of it. What we said is at the end of last year, it was a $250 million book of business growing at a minimum of 30% this year. Sam may have said it had an exit rate of $300 million or something. I'm not 100% sure. But it's a fast-growing portion of our portfolio. The margin rate on this business is accretive to the company average. We like the partnerships that we have formed. Thes...

We have not. I mean, originally, Function Health when they first launched the company, I think, had a price of north of $400. But now they're advertising $1 a day, $365 for one large wellness panel and then a check, a smaller panel later in the year. So no, we don't see people pricing against each other. WHOOP and Oura and the rest are about the same.

What analysts pressed on

Analysts expressed concerns regarding the slower pace of M&A activity and potential regulatory impacts from PAMA, questioning how these factors might affect future growth and profitability. There is also apprehension about the competitive landscape in the consumer health segment and pricing pressures.

Main topics on the call

• Shift in Growth Strategy — Management indicated a strategic pivot from M&A to organic growth, stating, "Most of this year's growth is primarily all organic." This change reflects a focus on integrating previous acquisitions and enhancing existing ...
• Core Business Stability — The core business remains robust, with management noting, "The physician -- our core book of business... is still structurally sound, stronger than it was post-COVID." This stability is attributed to ongoing chronic heal...
• Consumer Health Growth — The consumer health segment is rapidly expanding, with revenue projected to reach $300 million, growing at a minimum of 30%. Management highlighted that this segment's margin is "accretive to the company average," indica...
• Partnerships with Health Systems — Quest's partnerships with health systems like Corewell and Fresenius are expected to enhance margins over time, with management stating, "Next year should be accretive to the average margin rate of the company." This ref...

Read the full Quest Diagnostics Incorporated transcript (September 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 65 Quest Diagnostics Incorporated earnings call transcripts on record, spanning January 15, 2020 to September 15, 2026. Based on this history, Quest Diagnostics Incorporated reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

DGX

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

65

First call

January 15, 2020

Most recent

September 15, 2026

Reporting cadence

quarterly